Stryker (NYSE:SYK) Releases FY 2026 Earnings Guidance

Stryker (NYSE:SYK) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 14.900-15.100 for the period, compared to the consensus EPS estimate of 14.960. The company issued revenue guidance of -.

Stryker Price Performance

NYSE:SYK traded up $9.83 during mid-day trading on Friday, reaching $364.13. 1,257,481 shares of the stock were exchanged, compared to its average volume of 1,885,719. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. The business has a fifty day moving average price of $359.38 and a 200 day moving average price of $371.95. Stryker has a 1-year low of $329.16 and a 1-year high of $404.87. The firm has a market capitalization of $139.25 billion, a PE ratio of 47.95, a PEG ratio of 2.29 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $4.01 EPS. Research analysts expect that Stryker will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a $0.88 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s dividend payout ratio is currently 46.25%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SYK shares. Sanford C. Bernstein raised their price objective on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Wells Fargo & Company increased their price target on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Truist Financial dropped their price target on Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. UBS Group set a $408.00 price objective on shares of Stryker in a research note on Monday, October 13th. Finally, Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. Twelve equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $426.95.

Insider Buying and Selling

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 522,118 shares of company stock valued at $185,381,932. 5.90% of the stock is owned by company insiders.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $4.47 vs. consensus ~$4.40 and revenue $7.17B vs. ~$7.12B; adjusted operating margin expanded and organic sales growth remained double-digit, signaling underlying demand and operational leverage. Stryker press release
• Positive Sentiment: Stryker raised its full-year profit outlook and gave 2026 guidance for 8.0%–9.5% organic net?sales growth and adjusted EPS of $14.90–$15.10, backing a continuation of strong top?line momentum and margin expansion. Reuters: Stryker raises annual profit forecast
• Positive Sentiment: Needham raised its price target to $454 and reiterated a Buy, citing sustained double?digit growth and operating leverage — a fresh analyst upgrade that supports upside vs. the current share price. The Fly: Needham price target raise
• Neutral Sentiment: Management’s EPS guidance ($14.90–$15.10) is roughly in line with street expectations, implying limited surprise to FY26 consensus but confirming the company’s steady growth trajectory. GlobeNewswire: Stryker results & outlook
• Neutral Sentiment: Analysts note tariff and macro headwinds for 2026 but generally maintain Buy ratings because of Stryker’s diversified product mix and margin levers; watch FX and tariff developments. TipRanks: analyst note
• Negative Sentiment: Certain product areas show strain — spinal implants and some legacy items declined sharply year-over-year (partly from prior impairments/divestiture effects), which is a lingering segment-level risk to watch. Stryker press release (segment detail)
• Negative Sentiment: Recent insider sales and the company’s history of large one?time tax and goodwill adjustments add headline risk and could temper multiple expansion absent continued operational beats. QuiverQuant: additional context

Hedge Funds Weigh In On Stryker

A number of hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC raised its stake in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Credit Agricole S A bought a new stake in Stryker during the third quarter valued at about $194,045,000. Canada Pension Plan Investment Board lifted its holdings in Stryker by 132.8% during the second quarter. Canada Pension Plan Investment Board now owns 355,126 shares of the medical technology company’s stock valued at $140,498,000 after purchasing an additional 202,555 shares in the last quarter. Woodline Partners LP raised its position in shares of Stryker by 482.2% during the 3rd quarter. Woodline Partners LP now owns 130,505 shares of the medical technology company’s stock valued at $48,244,000 after purchasing an additional 108,090 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of Stryker by 75.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 235,484 shares of the medical technology company’s stock valued at $93,165,000 after buying an additional 101,137 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.